Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;3(1):35-47.
doi: 10.1016/j.ijsu.2005.03.011.

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections

Peter Fomin  1 , Mircea Beuran, Audrius Gradauskas, Giedrius Barauskas, Alexey Datsenko, Nathalie Dartois, Evelyn Ellis-Grosse, Evan Loh; Three Hundred Six Study Group
Affiliations
Free article

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections

Peter Fomin et al. Int J Surg. 2005.
Free article

Abstract

Background: Empiric treatment of complicated intra-abdominal infections (cIAI) represents a clinical challenge because of the diverse bacteriology and the emergence of bacterial resistance. The efficacy and safety of tigecycline (TGC), a first-in-class, expanded broad-spectrum glycylcycline antibiotic, were compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI.

Methods: In this prospective, double-blind, phase 3, multinational trial, patients were randomly assigned to intravenous (i.v.) TGC (100 mg initial dose, then 50 mg every 12 h) or i.v. IMI/CIS (500/500 mg every 6 h) for 5-14 days. Clinical response was assessed at the test-of-cure (TOC) visit (14-35 days after therapy) for microbiologically evaluable (ME) and microbiologically modified intent-to-treat (m-mITT) populations (co-primary efficacy endpoint populations in which cure/failure response rates were determined).

Results: Of 817 mITT patients (i.e., received > or = 1 dose of study drug), 641 (78%) comprised the m-mITT cohort (322 TGC, 319 IMI/CIS) and 523 (64%) were ME (266 TGC, 256 IMI/CIS). Patients were predominantly white (88%) and male (59%) with a mean age of 49 years. The primary diagnoses for the mITT group were complicated appendicitis (41%), cholecystitis (22%), and intra-abdominal abscess (11%). For the ME population, clinical cure rates at TOC were 91.3% (242/265) for TGC versus 89.9% (232/258) for IMI/CIS (95% CI -4.0, 6.8; P<0.001). Corresponding clinical cure rates within the m-mITT population were 86.6% (279/322) for TGC versus 84.6% (270/319) for IMI/CIS (95% CI -3.7, 7.5; P<0.001 for noninferiority TGC versus IMI/CIS). The most commonly reported adverse events for TGC and IMI/CIS were nausea (17.6% TGC versus 13.3% IMI/CIS; P=0.100) and vomiting (12.6% TGC versus 9.2% IMI/CIS; P=0.144).

Conclusions: TGC is efficacious in the treatment of patients with cIAIs and TGC met per the protocol-specified statistical criteria for noninferiority to the comparator, IMI/CIS.

PubMed Disclaimer

LinkOut - more resources